Shots: The company has reported the results from Part 2 of the FIREFISH study evaluating the efficacy and safety of Evrysdi in 41 infants aged 1-7 mos. with symptomatic Type […]readmore
Tags : Type 1 SMA
Shots: The 2-year data from Part 2 of P-II/III FIREFISH study involves assessing Evrysdi in 41 infants aged 1-7mos. with symptomatic Type 1 SMA Results: improvement in maintained motor function […]readmore
Shots: Roche has reported the data from the dose-finding Part 1 of the FIREFISH study assessing Evrysdi in patients aged 1-7mos. with Type 1 SMA. Part 1 evaluated several doses […]readmore
Shots: Roche reports the new 2-year data from Part 1 of the FIREFISH study assessing Evrysdi in infants aged 2-7mos. with symptomatic Type 1 SMA. The 2-year results in infants […]readmore